Vincenzo Callea

Summary

Country: Italy

Publications

  1. ncbi request reprint Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil
    Fortunato Morabito
    Haematologica 87:217-8. 2002
  2. ncbi request reprint Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy
    Vincenzo Callea
    Hematology Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Leuk Lymphoma 47:2314-20. 2006
  3. ncbi request reprint Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
    Massimo Martino
    Department of Bone Marrow Transplant, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 78:35-40. 2007
  4. ncbi request reprint High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Am J Hematol 81:973-8. 2006
  5. doi request reprint Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    Fortunato Morabito
    Unità Operativa di Ematologia, Azienda Ospedaliera dell Annunziata, 87100 Cosenza, Italy
    Eur J Haematol 84:223-8. 2010
  6. ncbi request reprint Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma
    Emilio Iannitto
    Hematology and BMT Unit, Department of Oncology, University of Palermo, Palermo, Italy
    Eur J Haematol 76:134-40. 2006
  7. doi request reprint Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial
    Emilio Iannitto
    Divisione di Ematologia e Trapianto di Midollo Osseo, Policlinico P Giaccone, Palermo, Italy
    Clin Lymphoma Myeloma 9:138-44. 2009
  8. doi request reprint Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
    Fortunato Morabito
    Unità Operativa Complessa di Ematologia, Azienda Ospedaliera, Cosenza, Italy
    Br J Haematol 146:44-53. 2009
  9. ncbi request reprint Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi
    Fortunato Morabito
    Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Cancer 101:1601-8. 2004
  10. ncbi request reprint Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma
    Fortunato Morabito
    Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 87:1192-9. 2002

Detail Information

Publications27

  1. ncbi request reprint Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil
    Fortunato Morabito
    Haematologica 87:217-8. 2002
    ....
  2. ncbi request reprint Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy
    Vincenzo Callea
    Hematology Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Leuk Lymphoma 47:2314-20. 2006
    ..In conclusion, SN development is dependent on the length of follow-up rather than on therapy duration. F + C should be administered with caution after prolonged CLB therapy...
  3. ncbi request reprint Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
    Massimo Martino
    Department of Bone Marrow Transplant, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 78:35-40. 2007
    ..1% to 76.5%). In conclusion, Thal as maintenance therapy after double ASCT is associated with low feasibility and high toxicity and could prevent a lengthy use of this antineoplastic agent...
  4. ncbi request reprint High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Am J Hematol 81:973-8. 2006
    ..In conclusion, an up-front tandem strategy with a very low reduced intensity-conditioning regimen for allografting following autografting is feasible and induces high CR/nCR rate in MM...
  5. doi request reprint Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    Fortunato Morabito
    Unità Operativa di Ematologia, Azienda Ospedaliera dell Annunziata, 87100 Cosenza, Italy
    Eur J Haematol 84:223-8. 2010
    ..In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI...
  6. ncbi request reprint Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma
    Emilio Iannitto
    Hematology and BMT Unit, Department of Oncology, University of Palermo, Palermo, Italy
    Eur J Haematol 76:134-40. 2006
    ..The purpose of the present study was to estimate the standardised incidence ratio (SIR) and the absolute excess risk (AER) of SPC in patients with splenic marginal zone lymphoma (SMZL)...
  7. doi request reprint Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial
    Emilio Iannitto
    Divisione di Ematologia e Trapianto di Midollo Osseo, Policlinico P Giaccone, Palermo, Italy
    Clin Lymphoma Myeloma 9:138-44. 2009
    ....
  8. doi request reprint Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
    Fortunato Morabito
    Unità Operativa Complessa di Ematologia, Azienda Ospedaliera, Cosenza, Italy
    Br J Haematol 146:44-53. 2009
    ..8, 95% confidence interval (CI) 2.4-5.8] and high-risk group (HR = 8.0, 95% CI 3.9-16.2). Specific transcriptional patterns were significantly associated with risk groups...
  9. ncbi request reprint Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi
    Fortunato Morabito
    Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Cancer 101:1601-8. 2004
    ..To assess the impact of T-cell/B-cell phenotype on clinical outcome, the authors retrospectively compared patients who had peripheral T-cell lymphoma, unspecified (PTCL-U), with patients who had diffuse large B-cell lymphoma (DLBCL)...
  10. ncbi request reprint Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma
    Fortunato Morabito
    Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 87:1192-9. 2002
    ..Furthermore, there are considerable concerns regarding the appropriate use of health care resources in order to reduce costs associated with PBSCT. One of the strategies attempted to reach this goal is outpatient-based PBSCT...
  11. ncbi request reprint Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro
    Fortunato Morabito
    Dipartimento di Ematologia Azienda, Ospedaliera Bianchi Melacrino, Reggio Calabria, Italy
    Haematologica 88:864-73. 2003
    ..The aim of this study was to ascertain whether B-CLL cells, induced into apoptosis, expressed surface CD10, since a correlation between apoptosis and CD10 expression has been demonstrated...
  12. ncbi request reprint Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera AO S Giovanni Battista, Turin, Italy
    Blood 109:2767-72. 2007
    ..Initial results showed that VMPT is an effective salvage therapy with a very high proportion of responses. The incidence of neurotoxicities was unexpectedly low...
  13. doi request reprint Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 112:3107-14. 2008
    ..34). These data confirm activity of MPT for PFS but failed to show any survival advantage. New agents in the management of relapsed disease could explain this finding. The study is registered at www.clinicaltrials.gov as #NCT00232934...
  14. ncbi request reprint Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy
    Lancet 367:825-31. 2006
    ..This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years...
  15. ncbi request reprint Splenic marginal zone lymphoma: a prognostic model for clinical use
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
    Blood 107:4643-9. 2006
    ..In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient...
  16. doi request reprint Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva
    Marco Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Blood 111:4004-13. 2008
    ..This trial was registered at www.clinicaltrials.gov as no. NCT00435955...
  17. ncbi request reprint Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Blood 104:3052-7. 2004
    ..Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients...
  18. ncbi request reprint Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Turin, Italy
    Cancer 104:1428-33. 2005
    ..No data are available on the association of thalidomide with oral melphalan and prednisone, still considered the standard treatment for elderly patients...
  19. ncbi request reprint The clinical value of tumor burden at diagnosis in Hodgkin lymphoma
    Paolo G Gobbi
    Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    Cancer 101:1824-34. 2004
    ..The authors investigated the clinical role of tumor burden (TB) in patients with Hodgkin lymphoma, relating this parameter to most of the current clinical and prognostic factors and to the best predictive multifactorial models...
  20. ncbi request reprint A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia
    Stefano Molica
    Medical Oncology Unit, Department of Oncology and Hematology, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy
    Leuk Lymphoma 46:553-60. 2005
    ....
  21. ncbi request reprint Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
    Sara Galimberti
    Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S Chiara Via Roma, 56 56100 Pisa, Italy
    Leuk Res 29:961-6. 2005
    ..01). These data sustain the relevant role of molecular monitoring in MM patients undergoing NMT. MRD monitoring would assist physicians in making additional therapeutic decisions to better control this hematological malignancy...
  22. ncbi request reprint Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplantation Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, 89100, Reggio, Calabria, Italy
    Support Care Cancer 13:182-7. 2005
    ..008). Independently of Hb levels at PBSCT, rHuEPO therapy was significantly associated with a lower risk of transfusion requirement. In conclusion, rHuEPO is shown to be effective when administered prior to high-dose therapy in MM...
  23. ncbi request reprint Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses
    Sonia Fabris
    Laboratorio di Ematologia Sperimentale e Genetica Molecolare, UO Ematologia 1, Dipartimento di Scienze Mediche, Universita degli Studi di Milano, Ospedale Maggiore IRCCS, Milan, Italy
    Genes Chromosomes Cancer 42:117-27. 2005
    ..Our data suggest the importance of using combined molecular cytogenetic and gene expression approaches to detect genetic aberrations in MM...
  24. ncbi request reprint Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma
    Michela Mattioli
    Laboratorio di Ematologia Sperimentale e Genetica Molecolare and U O Ematologia 1, Dipartimento di Scienze Mediche, Universita degli Studi di Milano, Ospedale Maggiore IRCCS, Milano, Italy
    Oncogene 24:2461-73. 2005
    ....
  25. ncbi request reprint Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system
    Luca Baldini
    Unità Operativa Ematologia 1, Dipartimento di Ematologia e Oncologia, Ospedale Maggiore, I R C C S, Milano, Italy
    J Clin Oncol 23:4662-8. 2005
    ....
  26. ncbi request reprint IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia
    Davide Bagnara
    Department of Experimental Medicine, Human Anatomy Section, University of Genoa, Genoa, Italy
    Br J Haematol 133:50-8. 2006
    ..We conclude that antigen stimulation and somatic hypermutation may participate in disease progression through the selection and expansion of neoplastic subclone(s)...
  27. ncbi request reprint Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations
    Luca Agnelli
    UO Ematologia 2, Centro G Marcora, Ospedale Maggiore Policlinico IRCCS, Dipartimento Scienze Mediche, Universita degli Studi di Milano, Via Francesco Sforza 35, 20122 Milano, Italy
    J Clin Oncol 23:7296-306. 2005
    ..In this study, we provide a molecular characterization of the identified translocations/cyclins (TC) groups...